Parainfluenza Clinical Trials

• Participants who, in the opinion of the investigator, can and will comply with the requirements of the protocol.

• Written or witnessed informed consent obtained from the participant (participant must be able to understand the informed consent) prior to performance of any study-specific procedure.

• A male or female participant 18-59 YOA at the time of the study intervention administration.

• Participants should be diagnosed with at least 1 of the following medical conditions if considered medically stable\* by the investigator:

‣ A stable condition is defined as a disease not requiring significant change (based on the investigator's opinion) in therapy or worsening during the 3 months before enrollment.

∙ Chronic cardiopulmonary disease resulting in activity restricting symptoms or use of long-term medication: oChronic obstructive pulmonary disease (COPD)

• Global Initiative for Chronic Obstructive Lung Disease (GOLD) Grade 2-4 oAsthma

• Patient on Maintenance and Reliever Therapy (MART) OR with at least one rescue treatment per week (excluding exercise asthma) oCystic fibrosis oOther chronic respiratory diseases: lung fibrosis, restrictive lung disease, interstitial lung disease, emphysema or bronchiectasis oChronic heart failure:

• A minimum of class II symptoms according to New York Heart Association classification of heart failure oPre-existing CAD (CAD not otherwise specified)

• Physician diagnosis of CAD based on electrocardiogram, exercise stress test, nuclear stress test, cardiac computed tomography scan or cardiac angiogram (more than the presence of hypercholesterolemia) oCardiac arrhythmia

• Patient diagnosed with a cardiac arrythmia that require medical support either pharmacologically or with a medical device -Diabetes mellitus: types 1 or 2 with active treatment for the past 6 months

⁃ Other diseases at increased risk for RSV disease oChronic kidney disease

• G2-G3 disease (Glomerular Filtration Rate between 30 and 90 mL/min/1.73 m2) oChronic moderate to severe liver disease

• Female participants of non-childbearing potential may be enrolled in the study. Non childbearing potential is defined as premenarche, hysterectomy, bilateral oophorectomy, bilateral salpingectomy or post-menopause.

• Female participants of childbearing potential may be enrolled in the study, if the participant:

‣ has practiced adequate contraception from 1 month prior to study intervention administration, and

⁃ has a negative pregnancy test on the day of study prior to intervention administration, and

⁃ has agreed to continue adequate contraception for at least 1 month after completion of the study intervention administration.